Genetic testing is required to confirm HER2 status before treatment with tucatinib

Tucatinib, also known as tucatinib, is a tyrosine kinase inhibitor targeting human epidermal growth factor receptor2 (HER2). For patients with HER2-positive breast cancer and colorectal cancer, tucatinib is undoubtedly a brand-new treatment strategy that brings them more hope for survival.

Tucatinib was originally combined with trastuzumab and capecitabine and is widely used to treat advanced, unresectable or metastatic breast cancerHER2-positive breast cancer. This combination therapy has shown significant results in patients who have already undergone other anti-HER2 treatments and whose cancer has spread to multiple locations, including the brain. The high selectivity of tucatinib and its unique property of penetrating the blood-brain barrier make it outstanding in the treatment of brain metastatic breast cancer.

In addition, tucatinib has also shown its unique efficacy in the treatment of colorectal cancer. For patients with HER2-positive, RAS wild-type metastatic colorectal cancer, when traditional chemotherapy drugs such as fluorouracil, oxaliplatin, and irinotecan can no longer control the progression of the disease, the combination therapy of tucatinib and trastuzumab has become a new and effective treatment option. This regimen is particularly suitable for patients who have received other chemotherapy drugs but whose condition continues to worsen or does not improve.

However, it is important to recognize that because tucatinib is specifically designed for patients with HER2-positive cancers, it is critical to undergo genetic testing to confirm a patient's HER2 status before initiating tucatinib treatment. Genetic testing not only helps doctors determine whether patients are suitable for tucatinib, but also provides patients with more precise and personalized treatment plans. In this way, not only can the treatment effect be improved, but unnecessary side effects can also be effectively reduced. Therefore, genetic testing is an essential step for patients who plan to use tucatinib to treat colorectal cancer.